TA
Takeda
TAK · NYSE
$18.36 -0.49% (-$0.09)
1M +5.13%
Market Cap ¥9.04T
P/E Ratio 49.65x
Div. Yield 1.74%
ROE 2.42%
Bulios Fair Price
$21.23
15.6% upside
Current Price
$18.36
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TAK is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
66 /100
Fair P/FCF 16.14x
P/E 49.65x
P/B 1.20x
Growth
48 /100
Stable FCF growth 33.04%
EPS growth 14.14%
Book val. growth 7.11%
Profitability
63 /100
Moderate Op. margin 10.99%
Gross margin 59.01%
FCF margin 12.02%
Quality
13 /100
Poor ROA 1.16%
ROIC 2.54%
Asset turnover 0.30x
Debt
45 /100
Moderate Int. coverage 1.86x
Debt/Equity 0.65x
Net debt/EBITDA 3.53x
Stability
46 /100
Moderate EPS volatility 76.77%
Beta 0.09x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TAK
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Julie So-Young Kim
Employees
47,029
Headquarters
Tokyo
Upcoming events
29 OCT
Earnings
Upcoming earnings report